Invasive cervical, vaginal, vulval, anal, or penile cancer · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall systemic events and general symptoms · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males
It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).
1 finding from 1 review
Mortality at up to 5‐year · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Clinical and harms outcomes* · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
1 finding from 1 review
Vomiting, retching, or antiemetics from 0‐2 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Vomiting, retching, or antiemetics 0‐12 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Anaphylactoid symptoms · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · people with both severe mental illness and substance misuse
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with both severe mental illness and substance misuse
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving study early: any reason compared with OLANZAPINE ‒ short‐ and long‐term data (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).
1 finding from 1 review
Substance use: improvement ‒ (at least 20% reduction in use, TLFB scale) · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes substance use: improvement ‒ (at least 20% reduction in use, TLFB… compared with CLOZAPINE ‐ all data short term (very low certainty).
1 finding from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
1 finding from 1 review